Seeking Drug Candidates to Address Transplant-related Complications

Asahi Kasei Pharma, a global pharmaceutical company, is seeking preclinical drug candidates for specific transplant complications with demonstrated in vitro efficacy, ideally supported by in vivo data. 

Approaches of Interest:

• High priority indications include transplant rejection, antibody-mediated rejection, delayed graft function, post-transplant lymphoproliferative disorder, transplant-associated thrombotic microangiopathy, chronic lung allograft dysfunction, cardiac allograft vaculopathy, whereas graft-versus-host disease is considered a lower priority 
• Open to biologics, small molecules, peptides and RNA-based approaches
• Novel drug candidates that are intended for use in combination with existing drugs are within scope 

Out of Scope:

• Drug repurposing 
• Cell therapy, probiotics, gene editing and AAV therapy 
• Diagnostic products, medical devices, platform technologies, drug screening libraries 
• Opportunities that focus solely on understanding mechanisms or exploring new targets 

Developmental Stages of Interest:

• Opportunities from preclinical research phase to late preclinical research stage are within scope, provided the efficacy has been confirmed in an in vitro study reflecting the treatment concept 
• It is desirable that the effectiveness has been confirmed in an in vivo study using an animal model of a transplant related target indication 

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions must include details on both the indication and the stage of development of the opportunity. Please provide this information using this submission form. If not provided, we may request this information before your submission is accepted. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.